Pharmaceutical

WCG ClinSphere™ Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection

CARY, N.C., March 27, 2025 /PRNewswire/ -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical…

9 months ago

MatchRX Launches Wholesale Expansion–Helping Pharmacies Slash Drug Costs

ROYAL OAK, Mich., March 27, 2025 /PRNewswire/ -- Independent pharmacies across the country are saving thousands on prescription drugs, thanks…

9 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer-…

9 months ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel,…

9 months ago

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives…

9 months ago

Wellgistics Health Annual Letter to Shareholders From the Office of the CEO March 2025

Dear Shareholders, TAMPA, FL, March 27, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (“Wellgistics Health”), This time last…

9 months ago

SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer

Chetan Pujara, Ph.D Chief Research & Development Officer, SpyGlass Pharma Dr. Pujara brings extensive industry experience to guide late-stage development…

9 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…

9 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

BOULDER, Colo., March 26, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced…

9 months ago

CytoSite Bio Announces Agreement with Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment

A global collaboration agreement has been signed for the development and commercialization of a Granzyme B-targeted Positron Emission Tomography (PET)…

9 months ago